CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma: a clinicopathologic study of 14 cases

Jaso, Jesse Manuel; Chen, Lei; Li, Shaoying; Lin, Pei; Chen, Weina; Miranda, Roberto N.; Konoplev, Sergej; Medeiros, L. Jeffrey; Yin, C. Cameron

doi:10.1016/j.humpath.2011.11.004

Cited by 45 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,18 However, expression of CD5 also has been detected occasionally in other B-cell lymphomas including extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone lymphoma, splenic marginal zone lymphoma, lymphoplasmacytic lymphoma, follicular lymphoma, and diffuse large B-cell CD5+ follicular lymphoma lymphoma. 9,[19][20][21][22][23] In follicular lymphoma, CD5 expression has been associated with younger age, male predominance and grade 3 morphology. 4,6,8 More recently, Miyoshi et al 10 in Japan reported a series of 22 cases of CD5+ follicular lymphoma and found that patients with CD5+ follicular lymphoma showed a higher frequency of peripheral blood involvement, CD25 and MUM1 expression, and a lower frequency of t(14;18)(q32;q21; Table 3).…”

Section: Discussionmentioning

confidence: 99%

CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases

Liu

Zuo

et al. 2015

Modern Pathology

Self Cite

View full text Add to dashboard Cite

Follicular lymphoma is a low-grade B-cell lymphoma of germinal center B-cell origin that typically lacks CD5 expression. We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women; median age, 60 years; range, 31-86). Follicular lymphoma was diagnosed initially in lymph nodes in 66 and extranodal sites in 22 patients. Eighty-one patients had lymphadenopathy, 66 had more than one involved site, 46 had bone marrow involvement, and 7 had splenomegaly. Staging information was available for 84 patients: 52 stage IV, 18 stage III, 12 stage II, and 2 stage I. Sixty-one cases were grade 1 or 2 and 27 were grade 3. The median proliferation index (Ki-67) was 30%. CD5 expression was detected by flow cytometry in 69, immunohistochemistry in 8, and both methods in 11 cases. The presence of t(14;18)(q32;q21)/IGH-BCL2 or other BCL2 translocation was detected in 28/44 (64%) cases. A total of 38 (43%) patients also had diffuse large B-cell lymphoma, concurrent with (n = 20), subsequent to (n = 13), or developing before CD5+ follicular lymphoma (n = 5). All patients received chemotherapy; 12 also received stem-cell transplantation. With a median follow-up of 55 months (range, 0.5-207), 15 patients died, 46 were alive with disease, and 20 were in clinical remission. Compared with a matched group of patients with CD5− follicular lymphoma, patients with CD5+ follicular lymphoma more commonly had an International Prognostic Index 42 (35/80 vs 10/99, Po0.001), more often developed diffuse large B-cell lymphoma (38/88 vs 17/99; Po 0.001), and had a shorter median progression-free survival (44 vs 89 months, P = 0.0042). Higher Ki-67 and International Prognostic Index were identified as poor prognostic factors in both the groups. We conclude that CD5 expression in follicular lymphoma is associated with a higher International Prognostic Index, higher rate of transformation to diffuse large B-cell lymphoma, and shorter progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 99%

CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases

Liu

Zuo

et al. 2015

Modern Pathology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast to the higher rates of nodal MZBCLs expressing CD5 (8.6%), 22 less than 1% of MALT lymphomas are positive for CD5. 23 Splenic MZBCLs exhibit positive CD5 expression in about 20% of the cases. 24,25 CD5 þ splenic MZBCL is closely related to its classic CD5 À counterpart, except for higher lymphocyte counts at diagnosis and more-diffuse bone marrow infiltration.…”

Section: 21mentioning

confidence: 99%

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang

Zu²

2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity.Objectives.-To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells.Data Sources.-Published and PubMed-indexed English literature was reviewed.Conclusions.-Although the presence or absence of CD5 and CD10 expression should be included in the initial immunohistochemistry screening panel for mature B-cell lymphomas, appropriate and judicial use of other B-cell antigens is necessary to ensure correct diagnoses. Furthermore, although the status of CD5 and CD10 expression is associated with certain prototypes of B-cell lymphomas, their expression is not specific. Plasma cells from plasma cell neoplasias and B-cell lymphomas exhibit overlapping but relatively distinct immunophenotypes; thus, a panel of immunohistochemical markers (CD19, CD45, CD56, and CD117) can be employed for their proper identification. Lastly, CD138 staining results are almost always positive in a group of aggressive B-cell lymphomas with plasmablastic features, including plasmablastic plasma cell myeloma, plasmablastic lymphoma, and ALK-1 þ large B-cell lymphoma.

show abstract

“…Histologically they are characterized by a monoclonal infi ltrate of small-to medium-sized cells with abundant cytoplasm and irregular nuclear contours, although larger centroblast-like cells may be present (Fig. Rarely, MALT lymphomas are CD5 positive and this is associated with a worse prognosis; these lymphomas may have cytogenetic changes such as trisomy 3 and del7q (Batstone et al 2003 ;Jaso et al 2012 ;Wenzel et al 2001 ). An essential pathologic feature is the presence of lymphoepithelial lesions with invasion of mucosal glands and crypts by aggregates of lymphoma cells associated with destruction.…”

Section: Pathology and Biologymentioning

confidence: 99%

Rare Lymphomas

2014

View full text Add to dashboard Cite

CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma: a clinicopathologic study of 14 cases

Cited by 45 publications

References 26 publications

CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases

CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Rare Lymphomas

Contact Info

Product

Resources

About